Prospective validation of tumor folate receptor expression density with the association of pafolacianine fluorescence during intraoperative molecular imaging-guided lung cancer resections.
Fluorescence-guided surgery
Folate receptor
Intraoperative molecular imaging
Lung cancer
Pafolacianine
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
10
2022
accepted:
08
02
2023
pmc-release:
01
07
2024
medline:
12
6
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Pafolacianine, a folate receptor alpha-targeted NIR tracer, has demonstrated clear efficacy in intraoperative molecular imaging-guided (IMI) lung cancer surgery. However, the selection of patients who would benefit from IMI remains challenging given the variability of fluorescence with patient-associated and histopathologic factors. Our goal in this study was to prospectively evaluate whether preoperative FRα/FRβ staining can predict pafolacianine-based fluorescence during real-time lung cancer resections. This was a prospective study conducted between 2018 and 2022 that reviewed core biopsy and intraoperative data from patients with suspected lung cancer. A total of 196 patients were deemed eligible, of whom core biopsies were taken from 38 patients and assessed for FRα and FRβ expression by immunohistochemistry (IHC). All patients underwent infusion of pafolacianine 24 h prior to surgery. Intraoperative fluorescence images were captured with the VisionSense bandpass filter-enabled camera. All histopathologic assessments were performed by a board-certified thoracic pathologist. Of the 38 patients, 5 (13.1%) were found to have benign lesions (necrotizing granulomatous inflammation, lymphoid aggregates) and 1 had metastatic non-lung nodule. Thirty (81.5%) had malignant lesions, with the vast majority (23, 77.4%) being lung adenocarcinoma (7 (22.5%) SCC). None of the benign tumors (0/5, 0%) exhibited in vivo fluorescence (mean TBR of 1.72), while 95% of the malignant tumors fluoresced (mean TBR of 3.11 ± 0.31) compared to squamous cell carcinoma (1.89 ± 0.29) of the lung and sarcomatous lung metastasis (2.32 ± 0.09) (p < 0.01). The TBR was significantly higher in the malignant tumors (p = 0.009). The median FRα and FRβ staining intensities were both 1.5 for benign tumors, while the FRα and FRβ staining intensities were 3 and 2 for malignant tumors, respectively. Increased FRα expression was significantly associated with the presence of fluorescence (p = 0.01), CONCLUSION: This prospective study sought to determine whether preoperative FRα and FRβ expression on core biopsy IHC correlates with intraoperative fluorescence during pafolacianine-guided surgery. These results, although of small sample size, including limited non-adenocarcinoma cohort, suggest that performing FRα IHC on preoperative core biopsies of adenocarcinomas as compared to squamous cell carcinomas could provide low-cost, clinically useful information for optimal patient selection which should be further explored in advanced clinical trials.
Identifiants
pubmed: 36905412
doi: 10.1007/s00259-023-06141-3
pii: 10.1007/s00259-023-06141-3
pmc: PMC10314365
mid: NIHMS1908252
doi:
Substances chimiques
Pafolacianine
F7BD3Z4X8L
Folic Acid
935E97BOY8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2453-2465Subventions
Organisme : NCI NIH HHS
ID : F32 CA254210
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA254859
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA251063
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Mol Ther. 2018 Feb 7;26(2):390-403
pubmed: 29241970
Oncotarget. 2012 Apr;3(4):414-25
pubmed: 22547449
Ann Surg. 2015 Oct;262(4):602-9
pubmed: 26366539
J Biomed Opt. 2021 May;26(5):
pubmed: 34002555
Transl Lung Cancer Res. 2022 Nov;11(11):2318-2331
pubmed: 36519017
Ann Thorac Surg. 2018 Mar;105(3):901-908
pubmed: 29397932
Front Oncol. 2015 May 26;5:113
pubmed: 26075181
Arch Pathol Lab Med. 2017 Jul;141(7):932-939
pubmed: 27763791
Ann Surg. 2022 Oct 1;276(4):711-719
pubmed: 35837887
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1205-17
pubmed: 15094216
Mol Imaging Biol. 2023 Feb;25(1):85-96
pubmed: 34101106
J Nucl Med. 2022 Nov;63(11):1620-1627
pubmed: 35953303
Surg Oncol. 2013 Sep;22(3):156-61
pubmed: 23702313
Respir Med Case Rep. 2018 May 23;25:9-11
pubmed: 29892540
JAMA. 2012 Jun 13;307(22):2418-29
pubmed: 22610500
Asian Pac J Cancer Prev. 2013;14(4):2533-40
pubmed: 23725170
JAMA Surg. 2021 Nov 1;156(11):1043-1050
pubmed: 34431971
Gynecol Oncol. 2019 Oct;155(1):63-68
pubmed: 31362825
Int J Mol Imaging. 2015;2015:469047
pubmed: 26491562
Theranostics. 2014 Aug 15;4(11):1072-84
pubmed: 25250092
Diagn Pathol. 2018 Feb 9;13(1):12
pubmed: 29426340
Signal Transduct Target Ther. 2020 Jan 22;5(1):6
pubmed: 32296026
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Surg Oncol Clin N Am. 2020 Oct;29(4):525-541
pubmed: 32883456
Ann Thorac Surg. 2022 Dec;114(6):2115-2123
pubmed: 34774493
Mol Imaging Biol. 2023 Jun;25(3):569-585
pubmed: 36534331
Mol Imaging Biol. 2023 Feb;25(1):156-167
pubmed: 35290565
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4406-4418
pubmed: 35876868